Experience with imatinib mesylate in children with Ph+ chronic myelogenous leukemia

被引：0
|
作者：
Kapoor, Gauri [1 ]
Abedin, Sarfrazu [1 ]
Garg, Pravesh [1 ]
Tyagi, Vinod [1 ]
Khullar, Paras [1 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, Delhi, India
来源：
PEDIATRIC BLOOD & CANCER | 2007年 / 49卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：528 / 528
页数：1
相关论文
共 50 条
  • [21] Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience
    Cojbasic, Irena
    Macukanovic-Golubovic, Lana
    VOJNOSANITETSKI PREGLED, 2010, 67 (10) : 802 - 806
  • [22] Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan
    Yasuhito Nannya
    Hiromitsu Yokota
    Yumiko Sato
    Go Yamamoto
    Takashi Asai
    Motoshi Ichikawa
    Takuro Watanabe
    Keiki Kumano
    Akira Hangaishi
    Tsuyoshi Takahashi
    Shigeru Chiba
    Yutaka Yatomi
    Mineo Kurokawa
    International Journal of Hematology, 2008, 88 : 159 - 164
  • [23] Secondary leukemia after imatinib mesylate (IM) therapy for chronic myelogenous leukemia (CML).
    Kovitz, CA
    Kantarjian, HM
    Garcia-Manero, G
    Abruzzo, LV
    Cortes, JE
    BLOOD, 2005, 106 (11) : 295B - 295B
  • [24] Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
    Cortes, J
    Talpaz, M
    O'Brien, S
    Jones, D
    Luthra, R
    Shan, J
    Giles, F
    Faderl, S
    Verstovsek, S
    Garcia-Manero, G
    Rios, MB
    Kantarjian, H
    CLINICAL CANCER RESEARCH, 2005, 11 (09) : 3425 - 3432
  • [25] Imatinib for chronic myelogenous leukemia -: single centre experience
    Michalovicova, Z.
    Demeckova, E.
    Tothova, J.
    Mistrik, M.
    BLOOD REVIEWS, 2007, 21 : S125 - S125
  • [26] Population pharmacokinetics of imatinib in patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase.
    Bin, P
    Schmidli, H
    Riviere, GJ
    Racine, A
    Capdeville, R
    BLOOD, 2002, 100 (11) : 784A - 784A
  • [27] Squamous cell carcinoma in a chronic myelogenous leukemia patient treated with imatinib mesylate
    Fujii, Mizue
    Iwasaki, Takeshi
    Takahashi, Ichiro
    Kishiyama, Kazunori
    Honma, Masaru
    Takahashi, Hidetoshi
    Ishida-Yamamoto, Akemi
    Iizuka, Hajime
    JOURNAL OF DERMATOLOGY, 2015, 42 (03): : 338 - 339
  • [28] Laboratory monitoring of chronic myelogenous leukemia patients on imatinib mesylate (Gleevec) therapy
    Shaw, GR
    LABORATORY MEDICINE, 2004, 35 (02) : 104 - 106
  • [29] Biomarkers for diagnosis and targeting of resistance and sensitivity to imatinib mesylate in chronic myelogenous leukemia
    Goldknopf, IL
    Sheta, EA
    Talpaz, M
    Cortes, J
    Albitar, M
    Kantarjian, H
    FASEB JOURNAL, 2006, 20 (04): : A499 - A499
  • [30] Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia
    Rastogi, Maynika V.
    Stork, Linda
    Druker, Brian
    Blasdel, Carolyn
    Thuan Nguyen
    Boston, Bruce A.
    PEDIATRIC BLOOD & CANCER, 2012, 59 (05) : 840 - 845
12345